SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalImmunomedics (IMMU) - moderated


Previous 10 Next 10 
To: mrc758 who wrote (52183)8/21/2019 9:52:35 PM
From: JohnBeach
2 Recommendations   of 59034
 
Late breaking abstract deadline was july 19. Daiichi said during their last earnings call that they would be providong an update at World Lung.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: JohnBeach who wrote (52180)8/22/2019 12:19:35 AM
From: duwhee
1 Recommendation   of 59034
 
I'm just glad the G's are not attending on the IMMU dime.
They'd bask in whatever accolades they could while delivering no return to IMMU on the investment of the trip and then come home with nothing more than the "Hello My Name is:" badge.

Share RecommendKeepReplyMark as Last Read


To: EagleRare who wrote (52181)8/22/2019 8:35:50 AM
From: TinfoilHat
10 Recommendations   of 59034
 
To stem the tide by drawing from the ether circuits, the Daiichi data to me is a super positive.

Either we are given a chance to showcase our safety profile vs theirs, and thus a comparison of linker technologies - remember DS1062 had a couple stinkers in prelim data whereas IMMU 132 has been recognized by KOLs to be sufficiently safe to consider combos with PARP inhibitors. An investigator from Harvard started his own trial for heavens sake, that is a strong signal. At ESMO don’t look at efficacy, look at safety of DS1062 to compare with Sacituzumab Govitecan.

Or, the Daichi data is great and we get a boost from having comparable technology. I have seen this countless times in recent weeks.

My reading of the stock price tea leaves is this has been a technical drop to the 13.70 level area to test support, likely stoked by the FDA wildcard. However, Patient advocacy groups will be hellbent if IMMU132 doesn’t get approval at the next go.

Remember, Tecentriq for TNBC got approved in March in the US. Patients who have recently started will need an option soon, and more than 50% are not eligible for tecentriq given lack of PDL1 expression. Patients need options asap, we have one on the shelf. Btw, Gottlieb may have had his thumb on our last application, and he has now been replaced by a guy from the NCI. We are on the glide slope...

Final toke from the ether signals for today: I think doright is Goldenberg and Bobbsy is Bezhad. That’s at least who I picture when each posts, keep up the good work you two.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: TinfoilHat who wrote (52186)8/22/2019 11:07:14 AM
From: bobbseytwins2001
3 Recommendations   of 59034
 
Hat, We take your contrast as a true compliment. Wish we were him.

Share RecommendKeepReplyMark as Last Read


To: TinfoilHat who wrote (52186)8/22/2019 12:37:57 PM
From: CelebrityEquity
1 Recommendation   of 59034
 
Let's acknowledge....you did write *TOKE*

Final toke from the ether signals for today: I think doright is Goldenberg and Bobbsy is Bezhad.
That’s at least who I picture when each posts, keep up the good work you two.







Share RecommendKeepReplyMark as Last Read


To: JohnBeach who wrote (52184)8/22/2019 8:27:45 PM
From: KeeptheFaith
   of 59034
 
JB or anyone, care to share baseless speculation or conspiracy on why it is not public yet? Just for fun in these news-depraved times. I’ll be.l boring and say administrative error by conference host.
(Instead of a Fuerstein-inspired fiasco)
- ktf

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


From: JJINV8/23/2019 12:45:54 AM
3 Recommendations   of 59034
 
They are not shy about hiring! Lots of activity. Interesting too the IT interest... I would assume as part of the overhaul of the process, new software systems in place, and that takes time... tick tock


Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: JJINV who wrote (52190)8/23/2019 7:45:33 AM
From: erickerickson
5 Recommendations   of 59034
 
"They are not shy about hiring!"

They weren't last time either. I was all excited last time by the hiring as a show of confidence. Which it was, even if misplaced. I'm not that excited this time, even if it does show confidence. "Once bitten, twice shy" comes to mind.

I do wonder what the head count now is .vs. January just before the CRL. About the only insight we have into what happened personnel-wise after the CRL is that they went to significant effort to keep the sales staff from bolting. And made some changes at the top for sure.

Other than that, we don't know much. My uninformed guess is that they made an effort to keep people they considered key from leaving and otherwise left positions open those who decided to move on. Now they're filling them back up again toward pre-CRL levels.

I have no evidence one way or the other if they "rightsized", but frankly I rather hope not as it would make hiring now more difficult.

So my guess is that now they're betting that they'll have a need (speedily I hope) for full staffing again and are starting to staff toward those levels. Let's claim that's true for a second. My (again guess) is that when the approach those levels is the time they're expecting the CRL, hope it's before Christmas, and I hope they're right this time.

That said, I don't have access to their personnel records so my guess is as good (or bad) as anyone else's.

And this is a job posting. The absolute minimum I'd guess is that it'd take a month to fill, and that's if there's an ideal candidate beating down the door. 2-3 months wouldn't surprise me at all, especially for the senior positions. Although what you can tell from job titles is anybody's guess. In my business, "Senior programmer" frequently seems to require "5+ years programming experience", a mere child IMO not "Senior" ;).

Just for yucks I tallied up the openings by when they were posted:

Last week
8
1-2 weeks ago
12
2-4 weeks ago
8
1 month ago
18
2+ months ago
17

So they're certainly not thinking they're going to close the doors any time soon! Mind you I'm encouraged, just not giddy this time around.

Anyway, enough. I have to go build some drawers for my workbench.

Share RecommendKeepReplyMark as Last Read


To: KeeptheFaith who wrote (52189)8/23/2019 9:39:42 AM
From: ladyPI
1 Recommendation   of 59034
 
Speculation - stock was already down 2 percent that day and news not as good as anticipated so letting stock get back up before 9/10 reveal

Share RecommendKeepReplyMark as Last Read


From: kdd9998/23/2019 3:20:31 PM
1 Recommendation   of 59034
 
Link to article on N of 1 trials, not only for already approved drugs, but future trials of new drugs. When done in cloud based setting, this has potential to greatly reduce cost vs RCT trials, plus it can help individual patient determine if a drug works for her. (These are individually blinded trials, but outcome is provided after the trial to each individual. How many of us with chronic diseases have argued with doctor that a medicine does more harm than good for us as individuals, even though it helps a percentage of the population as a whole.) They can statistically collect all the individuals results to determine overall population efficacy.

I think this might be a solution for emab lupus trials (although it still requires the cost of mfg the drugs). When I read this article, I was haunted by the pleas of the woman in our lupus trials who was noticeably helped by emab (she was able to go back to work) but had to go back to a life of misery after the trials ended.

The article says this may be a better way to test orphan drugs where it is hard to enroll enough patients.

the-scientist.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10